Urinary Tract Infection Treatment Market Estimated to Flourish by 2027

Posted by Aman Jaiswar on September 17th, 2019

Transparency Market Research has published a new report on the global Urinary Tract Infection Treatment Market. According to the report, the global urinary tract infection treatment market was valued at ~US$ 5.9 Bn in 2018, and is projected to expand at a CAGR of ~3% from 2019 to 2027.

Urinary tract infection (UTI) is a common infection caused due to the presence of a pathogen. E. coli is a common uropathogen that causes UTI. Antibiotics such as ciprofloxacin, cephalosporins, and penicillin are used for the treatment of urinary tract infection. Diagnostic tests and assays play a vital role in the screening and diagnosis of urinary tract infection.

In terms of disease, the complicated UTI segment held a major share of the global urinary tract infection treatment market in 2018. The segment is anticipated to dominate the global urinary tract infection treatment market during the forecast period, attributed to a decrease in the efficacy of therapies and increase in incidences of pathogen colonization. The segment is expected to grow at a rapid pace during the forecast period.

Based on drug class, the quinolones segment accounted for a major share of the urinary tract infection treatment market in 2018. The segment is likely to grow at a rapid pace during the forecast period. Rise in the number of physicians prescribing quinolones for the treatment of urinary tract infection is projected to drive the segment. Moreover, the introduction of new antibiotics due to microbial resistance is anticipated to fuel the growth of the segment.

To garner compelling insights on the forecast analysis of Global Urinary Tract Infection Treatment Market, Request a PDF Sample Here

In terms of pathogen, the E. coli segment held a major share of the urinary tract infection treatment market in 2018. The segment is expected to grow at a rapid pace during the forecast period. Increase in geriatric patients with urinary tract infection is likely boost the growth of the segment.

According to the World Health Organization, community-acquired UTI is most commonly caused due to E. coli. Based on source of infection, the hospital-acquired UTI segment accounted for a major market share in 2018. The segment is projected grow at a rapid pace during the forecast period due to an increase in the use of catheters during hospital stay. An article published in Skin Diseases and Skin Care stated that, 40% of urinary tract infections are hospital-acquired infections.

In terms of gender, the female segment is anticipated to grow at a rapid pace during the forecast period. An article published in NCBI indicated that, the prevalence of UTI in women ranges from 0.5 to 0.7 per person-years. Based on distribution channel, the hospital pharmacies segment held a major share of the UTI treatment market in 2018.